Ziekte van Crohn
CULTIVATE – Estrasimod
A multicenter, randomized, double-blind, parallel-group study to assess the efficacy and safety of oral Etrasimod as induction and maintenance therapy for moderately to severely active crohn’s disease.
SOPRANO-CD
Prevention of postoperative endoscopic recurrence with endoscopy-driven versus systematic biological therapy: a randomized, multicentre, parallel group pragmatic non-inferiority trial in adult patients with Crohn’s disease undergoing an ileocolonic resection with ileocolonic anastomosis.
FUZION – Guselkumab
A Phase 3, randomized, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of Guselkumab in participants with fistulizing, perianal crohn’s disease.
Colitis ulcerosa
VERDICT - Vedolizumab
In active ulcerative colitis, a randomIzed controlled trial for determination of the optimal treatment target.
ABTECT - Obefazimod
A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis.
DUET-UC - Guselkumab and Golimumab
A phase 2b randomized, double-blind, active- and placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of induction and maintenance combination therapy with Guselkumab and Golimumab in participants with moderately to severely active ulcerative colitis.
M21-446 - ABBV-668
A single-arm, open-label study to evaluate the efficacy and safety of ABBV-668 in subjects with moderate to severe ulcerative colitis.
Anthem UC
A phase 2b multicenter, randomized, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of JNJ-77242113 for the treatment of moderately to severely active ulcerative colitis.
AMBZ - Mirikizumab
A multicenter, phase 3b, open-label, single-arm study to investigate bowel urgency and its relationship with other outcome measures in adults with moderately to severely active ulcerative colitis treated with Mirikizumab.
Galocean - Filgotinib
A prospective, non-interventional, multi-country cohort study of the effectiveness and safety of filgotinib adult patients with moderately to severely active ulcerative colitis.
Ziekte van Crohn en colitis ulcerosa
FREE
De-escalation of anti-TNF therapy in adolescents and young adults with IBD with tight faecal calprotectin and trough level monitoring.
HYRISS – Hyrimoz (adalimumab biosimilar)
A multicenter, international, prospective, non-interventional, observational study, to assess treatment retention of an adalimumab biosimilar (Hyrimoz®) in IBD patients in real life setting.
Interesse of vragen?
- Mail naar studie.gastro@uzgent.be of bel 09 332 51 66 (Natalia Swietek, Emily Van Gucht en Femke Dieryck)